Genetic testing before tacrolimus in kidney transplant
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are on the waiting list for a kidney transplant.
- You have not had genetic testing for the CYP3A5 gene before.
- You are not allergic to tacrolimus (an anti-rejection medicine).
- You have not had a previous heart, liver, or kidney transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
This trial tests a new way to personalize tacrolimus dosing for children after a kidney, liver, or heart transplant. It uses genetic information and a formula to find the best starting dose, aiming to improve outcomes.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study tests a personalized approach to dosing tacrolimus (an anti-rejection medicine) in children who have had a kidney transplant. By using each child's own data, doctors hope to find the best dose to keep the transplanted kidney healthy and avoid side effects.
Hear when a new Immunosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.